Table 3.
Proportional hazard regression model for OS and DSS of MIBC patients by treatment information: RC vs. TMT.
| Characteristics | No. of patients | Overall survival (OS) | Disease-specific survival (DSS) | ||
|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | ||
| RC-MIBC cohort | 891 | 1.00 [reference] | 1.00 [reference] | ||
| TMT-MIBC cohort | 891 | 1.17 | 0.91-1.43 | 1.20 | 0.97-1.49 |
| Neoadjuvant chemotherapy (NAC) | |||||
| Yes | 36 | 1.10 | 0.51-2.03 | 1.08 | 0.45-2.14 |
| No | 855 | 1.18 | 0.90-1.48 | 1.19 | 0.86-1.53 |
| Adjuvant chemotherapy (AC) | |||||
| Yes | 515 | 1.08 | 0.88-1.47 | 1.09 | 0.86-1.50 |
| No | 376 | 1.21 | 0.77-1.69 | 1.23 | 0.74-1.71 |
| Radiation dose | |||||
| <60 Gy | 467 | 1.24 | 0.83-1.61 | 1.25 | 0.81-1.64 |
| ≥60 Gy | 424 | 1.06 | 0.79-1.43 | 1.09 | 0.77-1.45 |
| Response to chemoradiation | |||||
| Complete | 642 | 0.99 | 0.72-1.32 | 1.00 | 0.73-1.50 |
| Incomplete | 249 | 1.34 | 0.68-1.71 | 1.36 | 0.64-1.80 |
Analyses were based on the Cox PH regression. All baseline covariates were well balanced in the propensity score-matched sample. Therefore, only treatment information was controlled for in the final Cox PH regression model. OS: overall survival; DSS: disease-specific survival; HR: hazard ratio; CI: confidence interval; CI: confidence interval; RC: radical cystectomy; TMT: bladder-sparing trimodality therapy; MIBC: muscle-invasive bladder cancer.